Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma LSE:MTPH London Ordinary Share GB00BRTL9B63 ORD 0.005P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 121.00p 118.00p 124.00p 121.00p 121.00p 121.00p 0 07:48:35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.4 -11.2 -36.0 - 40.59

Midatech Pharma (MTPH) Latest News

More Midatech Pharma News
Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Share Charts

1 Year Midatech Pharma Chart

1 Year Midatech Pharma Chart

1 Month Midatech Pharma Chart

1 Month Midatech Pharma Chart

Intraday Midatech Pharma Chart

Intraday Midatech Pharma Chart

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
11/10/201615:05Midatech Pharma (MTPH) sees 10-fold increase15
30/9/201615:39Midatech Pharma PLC180

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
25/10/2016 13:19:15118.402,5082,969.47O
25/10/2016 10:12:09118.408841,046.66O
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

Midatech Pharma Daily Update: Midatech Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 121p.
Midatech Pharma has a 4 week average price of 123.90p and a 12 week average price of 135.82p.
The 1 year high share price is 282.50p while the 1 year low share price is currently 102.50p.
There are currently 33,542,412 shares in issue and the average daily traded volume is 9,602 shares. The market capitalisation of Midatech Pharma is £40,586,318.52.
jambo192: Singers and Panmure updates on research tree: "This morning’s trading H1 update indicates revenue in line with our expectations. We continue to believe that Midatech is at an interesting juncture, with the FDA filing of Q-Octreotide (a long-acting formulation of somatostatin) expected in the second half of the year and clinical trials for the company’s glioblastoma programme MTR103 due to commence in 2017e. We also continue to expect the group’s US speciality pharma operations to be cash generative from 2017e on a stand-alone basis." - Singers "Trading and revenues for the first half are in-line with updated expectations following positive guidance within the company’s 2015 results statement and we maintain our full-year forecasts. First-half revenues are expected to be £3.80m (1H15 £0.32m). It has been a tremendously busy period for Midatech both in terms of pipeline development and in terms of commercial activities – we remind investors, particularly, of the US launch of Zuplenz in April – and we consider the gap between our target price and the current share price unduly discounts the value opportunity." - Panmure
thomasthetank1: Read Panmure Gordon & Co's note on MIDATECH PHARMA, out this morning, by visiting hxxps:// "More good news this morning. Positive pharmacokinetic data from Midatech’s Q-Octreotide programme (MTD201) for the treatment of acromegaly and carcinoid syndrome demonstrate a favourable profile against the reference and market leader Sandostatin LAR Depot (Novartis). This paves the way towards IND submission and bio-equivalence in human studies expected in late 2016 and today’s news adds further weight and momentum to the company’s recent news flow. With significant headroom on the current share price ..."
thomasthetank1: Read Panmure's note on Midatech Pharma (MTPH), out this morning, by visiting … “Today’s FY15 results see revenues of £1.38m ahead of our expectations (PGe £1.30m, 2014: £0.16m) and, adjusting for one-off listing/acquisition items, the strong performance is also reflected at the bottom-line, with adjusted pre-tax loss of £9.9m vs PGe £10.6m loss. Delivery of this kind, during a period of high activity, reflects well on management capabilities and bandwidth. The parallel strands of commercial and pipeline development bode well for the long-term risk and growth profile of the business and we note strong revenues from marketed products in the first three months of 2016 with trading ‘slightly ahead of market expectations’. We retain our earnings forecasts unchanged for now but will look to future updates with respect to potential headroom on our forecasts. In the meantime, our view remains that there is significant headroom on the current share price…”
hutch_pod: Good interview. Liked hearing his view on the share price and Dara shareholder profit taking. Hope April delivers good progress.
hutch_pod: Did you see this from 17th? hTtp:// High time for an update on this article: the merger has been approved, the ADR's have been issued, but the idea so far hasn't worked out like I had planned. One of the risks highlighted in the article was: "Midatech's ADRs trading in tandem with its Ordinary Shares could cause the price of the ADRs to go up, but the same mechanism could obviously also cause the price of the Ordinary Shares in the UK to go down." Unfortunately, this is what happened. Since the deal was completed the MTPH share price in London took a bath and has now dropped close to 25% in about two weeks, making this deal a nightmare for the UK holders. I indicated in the article MTPH was illiquid and unshortable; I knew the shares in London would likely drop as a result of ADR-holders converting and selling, explaining some of the premium to the US price. But I hadn't expected an <20M take over to cause MTPH to shed >30M in market cap which in itself is of course fundamentally questionable; Midatech + DARA combined is now worth less than Midatech itself used to do. Also, trading volumes were horrendously low. I had expected MTPH-management, or any of its many experienced institutional investors, to see this coming based on the illiquidity of MTPH-shares, and to have at least something of contingency plan ready. Apparently so far they didn't. One would assume experienced investors like Neil Woodford (who holds an 18% stake through Woodford Investment Management) would not allow his fund to lose millions in a few days on trading volumes of about 40K $ without stepping in. One would also assume he, or any one of the other holders being hung out to dry, still will. It wouldn't take much. Anyway, with regards to ADR conversion: no US listed ADR I'm aware of trades at a discount to its UK listed peers, and MTP won't either in the mid term
njw2: The problem is quite simple, there is a major seller in the US line ( probably someone being stopped out from the total bulls up with the confusion on the merger )and until this is dealt with the share price collapse will continue. Maybe if someone at the company had a brain they would find the seller and take him out. Until that happens the share price will continue to collapse and there is no bottom on this.
deltrotter: They could well be in a closed period though tools with further news pending. The trading update in Q1 should make very interesting reading. I am peeved with the share price and their investor relations, but I am not peeved with their strategy and the execution of it.
Midatech Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20161026 07:30:43